Excellent post – – captures a good deal of my thinking. This last raise which was positioned as a “favor“ to shareholders was a real head-scratcher to me.

The notion that Nash alone could be worth billions to our company and yet we trade at a very small fraction of just that one indication, is also a head scratcher to me.

Having the feeling that we may have the most undervalued stock in the entire market right now is on one hand exciting, and on the other hand disturbing – – why has this disparity not been recognized by any company wanting to get in on the action, and wanting to pay handsomely (even over paying)?

So I am left feeling that one of two scenarios will play out:

1. I will wake up one day, and there will be a press release that starts a massive upward movement in the stock.

2. Despite the promise of this drug, the company runs out of money and is sold at an even lower price than it trades at now – – and I will look in the mirror and say “you should have known better“.

I hope it is number one, but I can’t say I’ll be completely shocked if number two plays out.